NCT00221624View on ClinicalTrials.gov

Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

November 30, 2001

Study Completion Date

April 30, 2004

Conditions

HCV InfectionHepatitis C, Chronic

Interventions

DRUG

Peginterferon alfa-2a

DRUG

ribavirin

DRUG

amantadine

Trial Locations (1)

33604

Service d'hépato-Gastro-Entérologie - Hôpital Haut Leveque - avenue de Magellan, Pessac

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Hospital, Bordeaux

OTHER

NCT00221624 - Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients | Biotech Hunter | Biotech Hunter